Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 5:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 2,938 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Weight Control Clear all
Completed No phase listed Observational Accepts healthy volunteers

Hormone Release and Stomach Disturbances in People With Binge Eating Disorder

NCT00307190
View directory record Official record
Conditions
Binge Eating Disorder, Obesity, Eating Disorders
Interventions
Not listed
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 28, 2012 · Synced Oct 24, 2026, 5:23 AM EDT
Completed Phase 2 Interventional

A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

NCT01271790
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Tegobuvir (GS-9190), GS-9451, Pegasys®, Copegus®, Tegobuvir placebo, GS-9451 placebo
Drug · Biological
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
85
States / cities
Dothan, Alabama • Montgomery, Alabama • Phoenix, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2014 · Synced Oct 24, 2026, 5:23 AM EDT
Not listed Not applicable Interventional

Knowledge-based Dietary Weight Management.

NCT04353726
View directory record Official record
Conditions
Weight Loss, Dietary Modifications, Obesity, Sustainability
Interventions
Weight management
Other
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
18 Years to 64 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Oct 24, 2026, 5:23 AM EDT
Completed Not applicable Interventional

Healthy Weight and Stress Management Study

NCT05279989
View directory record Official record
Conditions
Physical Disability, Obesity, Muscle Weakness, Anxiety, Depression
Interventions
Seated Tai Chi Qigong, Health Information Videos
Other
Lead sponsor
Arizona State University
Other
Eligibility
35 Years to 64 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 2, 2023 · Synced Oct 24, 2026, 5:23 AM EDT
Recruiting Phase 3 Interventional

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

NCT07684235
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Maridebart cafraglutide, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
3,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
71
States / cities
Anniston, Alabama • Daphne, Alabama • Mobile, Alabama + 57 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 24, 2026, 5:23 AM EDT
Active, not recruiting Phase 3 Interventional

Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

NCT06291376
View directory record Official record
Conditions
Immunoglobulin A Nephropathy, IgAN
Interventions
Ravulizumab, Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
584 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
39
States / cities
Alabaster, Alabama • Phoenix, Arizona • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 24, 2026, 5:23 AM EDT
Completed Phase 3 Interventional Results available

Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl

NCT01081132
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
Extended-release Guanfacine Hydrochloride, Placebo
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
13 Years to 17 Years
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
54
States / cities
Dothan, Alabama • Little Rock, Arkansas • Rolling Hills Estates, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Oct 24, 2026, 5:23 AM EDT
Terminated Not applicable Interventional

Development of Novel Behavioral Intervention for Sustainable Weight Loss in Hispanic Adults With Obesity

NCT03978416
View directory record Official record
Conditions
Obesity
Interventions
Healthy Weight for Living for Hispanics
Behavioral
Lead sponsor
Tufts University
Other
Eligibility
50 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Oct 24, 2026, 5:23 AM EDT
Completed Not applicable Interventional Results available

PREVENT Tool Study: Late Effects Clinic

NCT04530825
View directory record Official record
Conditions
Cardiovascular Disease, Childhood Obesity
Interventions
Wait-List Control, PREVENT Tool
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
12 Years to 19 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 25, 2023 · Synced Oct 24, 2026, 5:23 AM EDT
Completed Not applicable Interventional

Controlled Trial of WLS vs. CLI for Severely Obese Adolescents With NASH

NCT02412540
View directory record Official record
Conditions
Obesity, Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver Disease
Interventions
Comprehensive Lifestyle Intervention
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
12 Years to 19 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 24, 2026, 5:23 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Effects of a Nutritional Supplement Combination on Body Weight Management

NCT01725958
View directory record Official record
Conditions
Safety/Effacy
Interventions
Nutritional supplement and protein shakes
Dietary Supplement
Lead sponsor
Pharmanex
Industry
Eligibility
25 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Orem, Utah
Source: ClinicalTrials.gov public record
Updated Oct 29, 2014 · Synced Oct 24, 2026, 5:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Preventing Diabetes With Digital Health and Coaching

NCT03312764
View directory record Official record
Conditions
PreDiabetes
Interventions
Online diabetes prevention program, Standard Care
Behavioral
Lead sponsor
Omada Health, Inc.
Industry
Eligibility
19 Years and older
Enrollment
598 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 23, 2021 · Synced Oct 24, 2026, 5:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Feasibility of Healthy Dads Healthy Kids Latino

NCT03532048
View directory record Official record
Conditions
Feasibility
Interventions
The Papás Saludables, Niños Saludables Program, The Papás Saludables, Niños Saludables Wait-list Control
Behavioral
Lead sponsor
Baylor College of Medicine
Other
Eligibility
5 Years to 65 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Oct 24, 2026, 5:23 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of TAK-442 in Subjects Undergoing Total Knee Replacement

NCT00641732
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
TAK-442, Enoxaparin
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
1,045 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
38
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Oct 24, 2026, 5:23 AM EDT
Not yet recruiting Not applicable Interventional

Cognitive and Behavioral Approaches to Reduce Binge Eating and Excess Weight in Adolescents (Online)

NCT07856784
View directory record Official record
Conditions
Binge Eating, Overweight and Obesity, Eating Disorders in Adolescence
Interventions
Cognitive-Behavioral Therapy for Adolescent Binge Eating, Lifestyle Behavioral Obesity Intervention, Active Control
Behavioral · Other
Lead sponsor
Indiana University
Other
Eligibility
12 Years to 17 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 24, 2026, 5:23 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies

NCT03650452
View directory record Official record
Conditions
Epilepsy, Dravet Syndrome, Lennox-Gastaut Syndrome
Interventions
TAK-935, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
2 Years to 17 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
15
States / cities
Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 24, 2026, 5:23 AM EDT
Withdrawn Phase 1Phase 2 Interventional Accepts healthy volunteers

Platelet-Rich Plasma and the Effects of NSAIDs on Pain and Functional Scores in Knee Osteoarthritis

NCT05742763
View directory record Official record
Conditions
Osteoarthritis of the Knee, Degenerative Osteoarthritis, Knee Pain Chronic
Interventions
Ibuprofen and PRP, Acetaminophen and PRP, Placebo and PRP
Combination Product
Lead sponsor
QC Kinetix LLC
Industry
Eligibility
50 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 24, 2026, 5:23 AM EDT
Withdrawn Phase 2 Interventional

Anti-psychotic Medication (New Use) Weight Loss Study

NCT01272752
View directory record Official record
Conditions
Obesity
Interventions
IHBG-10, Placebo
Dietary Supplement
Lead sponsor
Avera McKennan Hospital & University Health Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Jun 1, 2012 · Synced Oct 24, 2026, 5:23 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Trial of Amitriptyline for Chronic Oral Food Refusal in Children 9 Months to 8 Years of Age

NCT01206478
View directory record Official record
Conditions
Chronic Oral Food Refusal
Interventions
Amitriptyline, Placebo, Megestrol
Drug
Lead sponsor
Ann Davis, PhD, MPH, ABPP
Other
Eligibility
9 Months to 8 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
3
States / cities
Kansas City, Kansas • New Orleans, Louisiana • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 15, 2016 · Synced Oct 24, 2026, 5:23 AM EDT
Active, not recruiting Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I)

NCT05775848
View directory record Official record
Conditions
Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)
Interventions
BBP-418 (ribitol), Placebo
Drug · Other
Lead sponsor
ML Bio Solutions, Inc.
Industry
Eligibility
12 Years to 60 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
13
States / cities
Little Rock, Arkansas • Irvine, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 24, 2026, 5:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Gender- and Culturally-Sensitive Weight Loss Intervention for Hispanic Males

NCT02783521
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Counseling sessions, Wait List Control
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 64 Years · Male only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 1, 2017 · Synced Oct 24, 2026, 5:23 AM EDT
Recruiting Phase 3 Interventional

A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

NCT07595549
View directory record Official record
Conditions
Obesity, Overweight and/or Obesity, Overweight
Interventions
PF-08653944, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
954 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
35
States / cities
Canoga Park, California • Escondido, California • Modesto, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 24, 2026, 5:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Trial to Assess Gastrointestinal Responses to Dietary Fibers in Adults Using Weight Loss Medications

NCT07012317
View directory record Official record
Conditions
Gastrointestinal Symptoms, Weight Loss, GLP-1
Interventions
High Fiber Bar with Inulin, High Fiber bar with Fiber Blend, High Fiber Bar with Resistant Starch type 4, Low Fiber Bar
Other
Lead sponsor
Midwest Center for Metabolic and Cardiovascular Research
Other
Eligibility
25 Years to 64 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
2
States / cities
Miami Gardens, Florida • Port Saint Lucie, Florida
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 24, 2026, 5:23 AM EDT
Recruiting Phase 2 Interventional

This is a Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Efficacy and Safety of 2 Weight-based Treatment Groups of Plecanatide Versus Placebo in Children and Adolescent Participants 6 to Less Than 18 Years of Age With FC

NCT07723924
View directory record Official record
Conditions
Functional Constipation (FC)
Interventions
plecanatide, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
29
States / cities
Birmingham, Alabama • Mobile, Alabama • Saraland, Alabama + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 24, 2026, 5:23 AM EDT